Background and purpose.  Recent clinical data suggest beneficial effects of ivabradine, a specific heart rate lowering drug, in heart failure patients. However, the mechanisms responsible for ivabradine benefit need to be fully clarified. Thus, we aimed to investigate functional/molecular changes in I(f) , i.e., the specific target of ivabradine, in the failing atrial and ventricular myocytes where this current is upregulated as a consequence of maladaptive remodelling. Experimental approach.  We investigated the effects of ivabradine on electrophysiological remodeling in atrial (LA) and ventricular (LV, RV) myocytes from post-MI rats, receiving ivabradine 10 mg.kg(-1) .day(-1) (MI + IVA) or vehicle (MI) for 90 days, with sham-operated (sham or sham + IVA) rats as controls. I(f) current was measured by patch-clamp; HCN channel isoforms and microRNA (miRNA-1 and miR-133) expression were evaluated by RT PCR. Key results.  Maximal specific conductance of I(f) was increased in MI versus sham in LV (62.6 ± 8.5 vs. 23.5 ± 7.2 pS/pF, P < 0.01) and LA myocytes (67.2 ± 11.4 vs. 21.1 ± 5.8 pS/pF, P < 0.05). Treatment with ivabradine resulted in a significant reduction of HR in both MI and sham rats (P < 0.05). In MI+IVA, I(f) overexpression was attenuated and HCN4 transcription reduced by 66\% and 54\% in LV and RV tissue versus MI rats (all P < 0.05). miR-1 and miR-133, which modulate post-transcriptional expression of HCN2 and HCN4 genes, were significantly increased in myocytes from MI + IVA. Conclusion and implication.  The beneficial effects of ivabradine may be due to the reversal of electrophysiological cardiac remodelling in post-MI rats by reduction of functional overexpression of HCN channels. This is attributable to transcriptional and post-transcriptional mechanisms.

Long term treatment with ivabradine in post-myocardial infarcted rats counteracts f-channel overexpression / S. Suffredini;F. Stillitano;L. Comini;M. Bouly;S. Brogioni;C. Ceconi;R. Ferrari;A. Mugelli;E. Cerbai. - In: BRITISH JOURNAL OF PHARMACOLOGY. - ISSN 0007-1188. - STAMPA. - 165:(2012), pp. 1457-1466. [10.1111/j.1476-5381.2011.01627.x]

Long term treatment with ivabradine in post-myocardial infarcted rats counteracts f-channel overexpression.

STILLITANO, FRANCESCA;MUGELLI, ALESSANDRO;CERBAI, ELISABETTA
2012

Abstract

Background and purpose.  Recent clinical data suggest beneficial effects of ivabradine, a specific heart rate lowering drug, in heart failure patients. However, the mechanisms responsible for ivabradine benefit need to be fully clarified. Thus, we aimed to investigate functional/molecular changes in I(f) , i.e., the specific target of ivabradine, in the failing atrial and ventricular myocytes where this current is upregulated as a consequence of maladaptive remodelling. Experimental approach.  We investigated the effects of ivabradine on electrophysiological remodeling in atrial (LA) and ventricular (LV, RV) myocytes from post-MI rats, receiving ivabradine 10 mg.kg(-1) .day(-1) (MI + IVA) or vehicle (MI) for 90 days, with sham-operated (sham or sham + IVA) rats as controls. I(f) current was measured by patch-clamp; HCN channel isoforms and microRNA (miRNA-1 and miR-133) expression were evaluated by RT PCR. Key results.  Maximal specific conductance of I(f) was increased in MI versus sham in LV (62.6 ± 8.5 vs. 23.5 ± 7.2 pS/pF, P < 0.01) and LA myocytes (67.2 ± 11.4 vs. 21.1 ± 5.8 pS/pF, P < 0.05). Treatment with ivabradine resulted in a significant reduction of HR in both MI and sham rats (P < 0.05). In MI+IVA, I(f) overexpression was attenuated and HCN4 transcription reduced by 66\% and 54\% in LV and RV tissue versus MI rats (all P < 0.05). miR-1 and miR-133, which modulate post-transcriptional expression of HCN2 and HCN4 genes, were significantly increased in myocytes from MI + IVA. Conclusion and implication.  The beneficial effects of ivabradine may be due to the reversal of electrophysiological cardiac remodelling in post-MI rats by reduction of functional overexpression of HCN channels. This is attributable to transcriptional and post-transcriptional mechanisms.
2012
165
1457
1466
S. Suffredini;F. Stillitano;L. Comini;M. Bouly;S. Brogioni;C. Ceconi;R. Ferrari;A. Mugelli;E. Cerbai
File in questo prodotto:
File Dimensione Formato  
Suffredini_et_al-2012-British_Journal_of_Pharmacology.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: DRM non definito
Dimensione 764.51 kB
Formato Adobe PDF
764.51 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/594745
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 51
  • ???jsp.display-item.citation.isi??? 49
social impact